Quantcast

Synimmune’s anti-tumor Flysyn verywell tolerated in study

Synimmune GmbH, a biotechnology company focusing on the development of innovative and effective anti-tumor antibodies for orphan hematopoietic malignancies, presented results of its first-in-human clinical study of FLYSYN, a novel Fc-optimized antibody, for the treatment of acute myeloid leukemia (AML) were presented at the American Society of Hematology (ASH) Annual Meeting in Orlando, Florida.

Read more

Roxadustat phase 3 show treatment of anaemia from chronic kidney disease: AstraZeneca, FibroGen

AstraZeneca and FibroGen’s pooled cardiovascular (CV) safety analyses showed that roxadustat, an oral first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), did not increase the risk of MACE, MACE+ and all-cause mortality in non dialysis-dependent (NDD) patients compared to placebo and dialysis-dependent (DD) patients compared to epoetin alfa, a current medicine used to treat anaemia.

Read more